BeiGene, Ltd. (NASDAQ:BGNE) Receives $241.21 Average Target Price from Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $241.21.

A number of brokerages have commented on BGNE. JMP Securities initiated coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. JPMorgan Chase & Co. raised their price target on BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Citigroup upped their price objective on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America cut their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th.

BeiGene Stock Performance

Shares of NASDAQ:BGNE opened at $236.10 on Friday. The stock has a market capitalization of $22.88 billion, a P/E ratio of -31.19 and a beta of 0.62. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. BeiGene has a 1-year low of $126.97 and a 1-year high of $248.16. The business has a 50-day moving average price of $202.89 and a two-hundred day moving average price of $171.18.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. During the same period last year, the company earned ($3.64) earnings per share. BeiGene’s quarterly revenue was up 56.1% on a year-over-year basis. Equities analysts predict that BeiGene will post -5.07 earnings per share for the current year.

Insider Buying and Selling at BeiGene

In related news, CEO John Oyler sold 6,175 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, COO Xiaobin Wu sold 5,556 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total transaction of $1,053,695.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO John Oyler sold 6,175 shares of the firm’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold 23,904 shares of company stock valued at $5,034,965 in the last three months. Corporate insiders own 7.43% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BGNE. Parkwood LLC lifted its stake in shares of BeiGene by 3.0% in the 4th quarter. Parkwood LLC now owns 6,464 shares of the company’s stock valued at $1,166,000 after purchasing an additional 191 shares during the period. Virtu Financial LLC raised its holdings in shares of BeiGene by 94.2% in the 4th quarter. Virtu Financial LLC now owns 5,319 shares of the company’s stock worth $959,000 after acquiring an additional 2,580 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after acquiring an additional 136,458 shares in the last quarter. LVW Advisors LLC boosted its stake in BeiGene by 50.2% during the 1st quarter. LVW Advisors LLC now owns 1,957 shares of the company’s stock valued at $306,000 after purchasing an additional 654 shares during the last quarter. Finally, XY Capital Ltd bought a new stake in BeiGene during the 1st quarter worth approximately $4,632,000. 48.55% of the stock is owned by institutional investors and hedge funds.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.